DaVita Trades at 12.1x Forward P/E Ahead of Projected 50.6% Q3 Earnings Growth
Question
DaVita Trades at 12.1x Forward P/E Ahead of Projected 50.6% Q3 Earnings Growth
Direct answer
A 50.6% EPS expansion against a 12.1x forward P/E multiple creates valuation rerating potential relative to the 19.68x industry average. — bullish pressure on DVA via earnings expansion against discounted forward multiple.
- Original publisher
- Market Ontology
- Evidence through
- 2026-10-04
- Published
- 2026-10-20
- Revision
- 1 · 2026-10-20
Cite as: Market Ontology, “DaVita Trades at 12.1x Forward P/E Ahead of Projected 50.6% Q3 Earnings Growth”, revision 1, evidence through 2026-10-04. https://marketontology.com/catalysts/2026-10-04/davita-trades-at-12-1x-forward-p-e-ahead-of-projected-50-6-q3-earnings-growth-4602b3
| Asset | Direction | Timeframe | Channel | Score |
|---|---|---|---|---|
| DVA | ▲Bull | 1–4 weeks | earnings expansion against discounted forward multiple | 57 |
DaVita Trades at 12.1x Forward P/E Ahead of Projected 50.6% Q3 Earnings Growth
A 50.6% EPS expansion against a 12.1x forward P/E multiple creates valuation rerating potential relative to the 19.68x industry average. — bullish pressure on DVA via earnings expansion against discounted forward multiple.
DVA trades at 12.1x forward P/E versus 19.68x industry average with 50.6% EPS growth
- SourceDVA trades at 12.1x forward P/E versus 19.68x industry average with 50.6% EPS growth
- TransmissionA 50.6% EPS expansion against a 12.1x forward P/E multiple creates valuation rerating potential relative to the 19.68x industry average.
- SummaryDaVita shares gained 1.33% to close at $178.69. Consensus forecasts target Q3 EPS of $3.78, up 50.6% year-over-year. Forward valuation sits at 12.1x forward earnings compared to the 19.68x industry peer average.
- DVADirect directional exposure
Illustrative, not advice
- Crowded positioning may already reflect the move
- Counter-catalyst could neutralize the thesis before window closes
- DVA closes below pre-catalyst level on rising volume
- Catalyst narrative is officially walked back or contradicted
- Cross-asset confirmation (rates / FX / vol) reverses direction
- DVA price vs. pre-event level
- DVA volume vs. 20-day average
What happened next
Price follow-up pending — no stored daily closes for these assets yet.
Closing prices from stored daily bars; returns measured from the last close on or before the event date. Not a recommendation.
Sources
- DaVita HealthCare (DVA) Laps the Stock Market: Here's Why · media · 2026-10-02
Related catalysts
- 2026-10-11DaVita Outperforms S&P 500 on Projected 50.6% Dialysis EPS ExpansionDVA XLV+3.45%
- 2026-10-11DaVita Outperforms S&P 500 on Projected 50.6% Dialysis EPS ExpansionDVA
- 2026-10-11DaVita Projects 50.6% Quarterly EPS Growth at 12.15x Forward Earnings MultipleDVA
- 2026-10-11DaVita Projects 50.6% Quarterly EPS Growth at 12.15x Forward Earnings MultipleDVA
- 2026-10-10DaVita Gains as Forward P/E Holds at 12.15x Against 50.6% Projected EPS GrowthDVA
- 2026-10-10DaVita Outpaces S&P 500 on Forecast 50.6 Percent Quarterly EPS GrowthDVA SPY-1.97%
- 2026-10-10DaVita Gains as Forward P/E Holds at 12.15x Against 50.6% Projected EPS GrowthDVA
- 2026-10-10DaVita Gains 1.3% to $179.25 with Q3 EPS Projected Up 50.6% YoYDVA
See today's live cards
Public pages are published 24 hours after the product shows them. Desk shows every catalyst, event and causal reading as it happens, mapped to your holdings.